Results of Open Offer and General Meeting
21 Dec 2020

RNS Number : 3958J
Redx Pharma plc
21 December 2020

THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Redx Pharma plc
(“Redx” or “the Company”)

Results of Open Offer and General Meeting

Alderley Park, 21 December 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis announces the results of its Open Offer and General Meeting.

On 2 December 2020, Redx announced that it had conditionally raised £25.5 million by means of a Placing of 45,603,575 new Ordinary Shares (the “Placing Shares”) at 56 pence per share (the “Issue Price”). In addition, all Qualifying Shareholders were provided with an opportunity to subscribe for an aggregate of up to 3,904,948 Open Offer Shares on the basis of 1 Open Offer Share for every 50 existing Ordinary Shares held on the Record Date, at the Issue Price.

The Company has conditionally raised £128,837 through the Open Offer, having received valid acceptances in respect of 230,066 Open Offer Shares from Qualifying Shareholders, representing approximately 5.89 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will be satisfied in full.
Directors participation was as follows:

<table>
<thead>
<tr>
<th>Director</th>
<th>Placing shares subscribed for</th>
<th>Open offer shares subscribed for</th>
<th>Post subscription holding</th>
<th>% of post transaction share capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iain Ross</td>
<td>–</td>
<td>35,130</td>
<td>251,000</td>
<td>0.09</td>
</tr>
<tr>
<td>Peter Presland</td>
<td>–</td>
<td>27,376</td>
<td>146,225</td>
<td>0.05</td>
</tr>
<tr>
<td>Sarah Gordon Wild</td>
<td>892,858</td>
<td>–</td>
<td>892,858</td>
<td>0.33</td>
</tr>
<tr>
<td>Lisa Anson</td>
<td>89,286</td>
<td>–</td>
<td>89,286</td>
<td>0.03</td>
</tr>
</tbody>
</table>

The Placing and Open Offer was conditional, amongst other things, upon the passing of certain Resolutions at the General Meeting, held today at 11am. All the Resolutions proposed at the General Meeting were duly passed by the requisite majority.

The Placing Shares, the new Ordinary Shares to be issued pursuant to the Open Offer and the Conversion Shares are expected to be admitted to trading on AIM on 22 December 2020.

Capitalised terms used in this announcement shall, unless defined otherwise, have the same meaning as in the announcement of the Placing and Open Offer made by the Company on 2 December 2020.

For further information, please contact:

**Redx Pharma Plc**  
T: +44 1625 469 918

Iain Ross, Chairman
About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx’s lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company’s selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company’s core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary
Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END